EP Patent

EP1254143B1 — Lipid-based drug delivery systems

Assigned to Liplasome Pharma ApS · Expires 2004-09-29 · 22y expired

What this patent protects

The present invention relates to a lipid based drug delivery system for administration of a drug substance, wherein the drug substance is incorporated in the system, said system including lipid derivatives which has (a) an aliphatic group of a length of at least 7 carbon atoms an…

USPTO Abstract

The present invention relates to a lipid based drug delivery system for administration of a drug substance, wherein the drug substance is incorporated in the system, said system including lipid derivatives which has (a) an aliphatic group of a length of at least 7 carbon atoms and an organic radical having at least 7 carbon atoms, and (b) a hydrophilic moiety, where the lipid derivative furthermore is a substrate for extracellular phospholipase A2 to the extent that the organic radical can be hydrolytically cleaved off, said system having included therein lipopolymers or glycolipids so as to present hydrophilic chains on the surface of the system.

Drugs covered by this patent

Patent Metadata

Patent number
EP1254143B1
Jurisdiction
EP
Classification
—
Expires
2004-09-29
Drug substance claim
No
Drug product claim
No
Assignee
Liplasome Pharma ApS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.